TP53 and pancreatic neoplasm: Since pancreatic cancers carry activating mutations in KRAS, loss-of-function mutations in TP53, and CDKN2A in >90%, 50%, and 80% of tumours respectively, controlling CDKs might significantly impact PDAC [3,141,142,143].